Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Menatetrenone

Drug Profile

Menatetrenone

Alternative Names: E 0167; EA 0167; Glakay; KayTwo; Kaytwo® Syrup 0.2%; Menaquinone-4; MK 4; MQ 4; Vitamin K2

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Class Calcium regulators; Naphthoquinones; Osteoporosis therapies; Vitamins
  • Mechanism of Action Osteogenesis stimulants; Prostaglandin receptor antagonists; Vitamin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postmenopausal osteoporosis; Vitamin deficiency
  • Discontinued Liver cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 May 2012 Registered for the prevention of Vitamin K deficiency haemorrrhage (0.2% syrup) in neonates and infants in Japan (PO)
  • 22 Oct 2004 Phase-II clinical trials in liver cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top